This Phase 3b trial evaluated a higher investigational dose of semaglutide (7.2 mg, compared to the currently approved 2.4 mg dose) in 1,407 adults with obesity without diabetes over 72 weeks: The 7.2 mg dose achieved an average weight loss of approximately 1921% of total body weight approaching results previously seen only with tirzepatide (Zepbound) Nearly half of participants on the 7.2 mg dose achieved 20% weight loss a threshold previously associated only with bariatric surgery or the most potent dual-agonist medications The currently approved 2.4 mg dose achieved approximately 16% average weight loss in the same trial, consistent with earlier STEP data While the 7.2 mg dose is not yet FDA-approved, the STEP UP data represent an exciting frontier in semaglutide therapy and underscore the continued evolution of this class of medications
Because these medications work in part by slowing how quickly food leaves the stomach, the most frequent GLP-1 side effects are gastrointestinal symptoms, such as: Nausea Vomiting Diarrhea Constipation Upset stomach or heartburn These symptoms are usually most pronounced during the first few weeks of treatment or after a dose increase
Official site: Operating entity: Superior Health Solutions LLC, doing business as Telos Rx
These peptides are present in various biological processes and can have significant effects on the health and functioning of the human body, including the oral cavity [32]
These liposomes act as a protective barrier and shield the glutathione from stomach acid and digestive enzymes
Frontiers in Aging Neuroscience 2016
.png)
